Compare · MLTX vs NVO
MLTX vs NVO
Side-by-side comparison of MoonLake Immunotherapeutics (MLTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MLTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 162.7x MLTX ($1.32B).
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for MLTX).
- Both have 25 recent analyst ratings on file.
- Company
- MoonLake Immunotherapeutics
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $1.32B
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 25
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MLTX
- Amendment: SEC Form SCHEDULE 13G/A filed by MoonLake Immunotherapeutics
- SEC Form S-8 filed by MoonLake Immunotherapeutics
- SEC Form S-3ASR filed by MoonLake Immunotherapeutics
- SEC Form 10-Q filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
- Chief Scientific Officer Reich Kristian sold $22,000 worth of Class A ordinary shares (1,100 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Reich Kristian sold $1,049,960 worth of Class A ordinary shares (52,448 units at $20.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Reich Kristian sold $877,933 worth of Class A ordinary shares (43,700 units at $20.09) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Reich Kristian sold $322,261 worth of Class A ordinary shares (16,105 units at $20.01) as part of a pre-agreed trading plan (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S